340 related articles for article (PubMed ID: 34274492)
41. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
42. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients.
Leclerc M; Redjoul R; Le Bouter A; Beckerich F; Robin C; Parinet V; Pautas C; Menouche D; Bouledroua S; Roy L; Cabanne L; Nait-Sidenas Y; Fourati S; Maury S
J Hematol Oncol; 2022 Mar; 15(1):27. PubMed ID: 35303906
[TBL] [Abstract][Full Text] [Related]
43. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
[TBL] [Abstract][Full Text] [Related]
44. Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation.
Barabino L; Galitzia A; Murru R; Caocci G; Targhetta C; Greco M; Angioni G; Mulas O; Vacca A; Piras E; Frau V; Costa A; La Nasa G
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(23):8984-8989. PubMed ID: 36524517
[TBL] [Abstract][Full Text] [Related]
45. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.
Ram R; Hagin D; Kikozashvilli N; Freund T; Amit O; Bar-On Y; Beyar-Katz O; Shefer G; Moshiashvili MM; Karni C; Gold R; Kay S; Glait-Santar C; Eshel R; Perry C; Avivi I; Apel A; Benyamini N; Shasha D; Ben-Ami R
Transplant Cell Ther; 2021 Sep; 27(9):788-794. PubMed ID: 34214738
[TBL] [Abstract][Full Text] [Related]
46. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
47. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
48. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines.
McMurry R; Lenehan P; Awasthi S; Silvert E; Puranik A; Pawlowski C; Venkatakrishnan AJ; Anand P; Agarwal V; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Carlson K; Doddahonnaiah D; Metzger A; Kayal N; Berner G; Ramudu E; Carpenter C; Wagner T; Rajasekharan A; Soundararajan V
Med; 2021 Aug; 2(8):965-978.e5. PubMed ID: 34230920
[TBL] [Abstract][Full Text] [Related]
49. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
[TBL] [Abstract][Full Text] [Related]
50. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
51. Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks.
Esmaeilzadeh A; Maleki AJ; Moradi A; Siahmansouri A; Yavari MJ; Karami P; Elahi R
Expert Rev Vaccines; 2022 Oct; 21(10):1377-1394. PubMed ID: 35986451
[TBL] [Abstract][Full Text] [Related]
52. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
[TBL] [Abstract][Full Text] [Related]
53. Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
Nguyen S; Bastien E; Chretien B; Sassier M; Defer G; Nehme A; Lelong-Boulouard V; Alexandre J; Fedrizzi S; Morice PM
Ann Neurol; 2022 Dec; 92(6):1080-1089. PubMed ID: 36054163
[TBL] [Abstract][Full Text] [Related]
54. Compliance with yellow fever and measles vaccines in the revaccination program post-hematopoietic cell transplantation.
de Almeida Testa LH; Simione AJ; Dos Santos ACF; Colturato I; Barbieri F; de Souza MP; Colturato VR; Machado CM
Transpl Infect Dis; 2023 Aug; 25(4):e14098. PubMed ID: 37428874
[TBL] [Abstract][Full Text] [Related]
55. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
[TBL] [Abstract][Full Text] [Related]
56. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS.
Yan MM; Zhao H; Li ZR; Chow JW; Zhang Q; Qi YP; Wu SS; Zhong MK; Qiu XY
Front Pharmacol; 2022; 13():921760. PubMed ID: 36419624
[No Abstract] [Full Text] [Related]
57. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Gounant V; Ferré VM; Soussi G; Charpentier C; Flament H; Fidouh N; Collin G; Namour C; Assoun S; Bizot A; Brouk Z; Vicaut E; Teixeira L; Descamps D; Zalcman G
J Thorac Oncol; 2022 Feb; 17(2):239-251. PubMed ID: 34798306
[TBL] [Abstract][Full Text] [Related]
59. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
[TBL] [Abstract][Full Text] [Related]
60. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
